Colorectal Cancer Screening and Diagnostic Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2030, Segmented By Screening Method (Fecal Occult Blood Tests (FOBT), Colonoscopy, Sigmoidoscopy, CT Colonography (Virtual Colono

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	400 Pages	BlueWeave Consulting	January, 2024	BLWC18529281

Best Price Guarantee
Price	from $4,850
Length	400 Pages
Publisher	BlueWeave Consulting
Published Date	January, 2024
SKU	BLWC18529281

Global Colorectal Cancer Screening and Diagnostic Market Size Expands at CAGR of 8.95% to Reach USD 26.71 Billion by 2030

Global Colorectal Cancer Screening and Diagnostic Market is flourishing because of the rising incidence of colorectal cancer and a growing focus on the treatment of the disease and the management of increasing healthcare expenditure.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Global Colorectal Cancer Screening and Diagnostic Market size at USD 15.97 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects the Global Colorectal Cancer Screening and Diagnostic Market size to expand at a CAGR of 8.95% reaching a value of USD 26.71 billion by 2030. The growing incidence of colorectal cancer and the expansion of government initiatives to support early detection and screening for cancer are two of the key growth drivers for the Global Colorectal Cancer Screening and Diagnostic Market. Moreover, increased private investments in the launch of innovative and advanced technologies in cancer screening and diagnostics are predicted to proliferate in the Global Colorectal Cancer Screening and Diagnostic Market over the forecast period.

Opportunity: Rising incidences of colorectal cancer

The primary driver of growth for the Global Colorectal Cancer Screening and Diagnostic Market is the disease's increasing prevalence. About 10% of cancer cases are colorectal cancer, which ranks as the third most frequent kind of cancer, according to the World Health Organization. Colorectal cancer is linked to bad lifestyle choices made by individuals, such as consuming large amounts of processed meat and limited vegetables and fruits, obesity, smoking, and drinking alcohol. Consequently, healthcare providers advise anyone aged over 50 years or those with a family history of colorectal cancer to undergo routine tests.

Impact of Escalating Geopolitical Tensions on Global Colorectal Cancer Screening and Diagnostic Market

The escalating geopolitical tensions are disrupting the growth of the Global Colorectal Cancer Screening and Diagnostic Market. For instance, Ukraine is a leading medical tourism destination for the diagnosis and treatment of cancer. However, Russia's invasion of Ukraine and the outbreak of war between the two countries led to the inaccessibility of healthcare services. According to a paper published in the National Center for Biotechnology Information, the conflict led to the displacement of patients to safer regions, particularly Europe, which overburdened the healthcare sector in these countries due to the large number of refugees. As a result, the inaccessibility of cancer screening and diagnosis hindered overall global market growth.

Global Colorectal Cancer Screening and Diagnostic Market

Segmental Coverage

Global Colorectal Cancer Screening and Diagnostic Market – By End User

Based on end user, the Global Colorectal Cancer Screening and Diagnostic Market is segmented into hospitals & clinics, diagnostic centers, and research institutes. The hospitals & clinics segment accounts for the highest market share owing to the high number of hospitals and the increasing number of awareness campaigns. Additionally, favorable reimbursement policies and insurance coverage also favor the growth of the hospital segment in the market. The diagnostic centers are predicted to register a substantial growth rate during the forecast period. The growth of diagnostics segment is attributed to the rising number of colonoscopies for colorectal cancer screening.

Global Colorectal Cancer Screening and Diagnostic Market - By Region

The in-depth research report on the Global Colorectal Cancer Screening and Diagnostic Market the market in a number of major countries across five major regions: North America, Europe, Asia Pacific (APAC), Latin America, and Middle East and Africa. North America dominates the Global Colorectal Cancer Screening and Diagnostic Market owing to the rising incidences of the disease. According to estimates by the American Society of Clinical Oncology, colorectal cancer is the fourth most diagnosed cancer in the United States, with an estimated 52,550 deaths in 2023. Colorectal cancer screenings are generally recommended for people over the age of 50. However, the Washington Post reports that colorectal cancer is increasingly gaining prevalence among American youth, which is anticipated to drive the demand for colorectal cancer screening and diagnosis in North America during the forecast period.

Competitive Landscape

Major players operating in the Global Colorectal Cancer Screening and Diagnostic Market include Epigenomics Inc., Exact Sciences Corporation, Eiken Chemical Co. Ltd, Polymedco Inc., F. Hoffmann-La Roche AG, Siemens Healthineers AG, Sysmex Corporation, Olympus Corporation, Biocept Inc., and Pathway Genomics Corporation.

To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and the Global Colorectal Cancer Screening and Diagnostic Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Colorectal Cancer Screening and Diagnostic Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

1. Research Framework: 1.1. Research Objective; 1.2. Product Overview; 1.3. Market Segmentation
2. Executive Summary
3. Global Colorectal Cancer Screening and Diagnostic Market Insights: 3.1. Industry Value Chain Analysis; 3.2. DROC Analysis; 3.2.1. Growth Drivers; 3.2.1.1. Increasing Incidence of Colorectal Cancer; 3.2.1.2. Growing Healthcare Expenditure; 3.2.2. Restraints; 3.2.2.1. High Costs Associated with Colorectal Cancer Screening and Diagnostic Procedures; 3.2.2.2. Lack of Awareness about Colorectal Cancer; 3.2.3. Opportunities; 3.2.3.1. Government Initiatives and Awareness Campaigns; 3.2.3.2. Integration of Telemedicine and Digital Health Solutions; 3.2.4. Challenges; 3.2.4.1. Data Security and Privacy Concerns; 3.3. Technological Advancements/Recent Developments; 3.4. Regulatory Framework; 3.5. Porter’s Five Forces Analysis; 3.5.1. Bargaining Power of Suppliers; 3.5.2. Bargaining Power of Buyers; 3.5.3. Threat of New Entrants; 3.5.4. Threat of Substitutes; 3.5.5. Intensity of Rivalry
4. Global Colorectal Cancer Screening and Diagnostic Market Overview: 4.1. Market Size & Forecast, 2019–2030; 4.1.1. By Value (USD Billion); 4.2. Market Share and Forecast; 4.2.1. By Screening Method; 4.2.1.1. Fecal Occult Blood Tests (FOBT); 4.2.1.2. Colonoscopy; 4.2.1.3. Sigmoidoscopy; 4.2.1.4. CT Colonography (Virtual Colonoscopy); 4.2.1.5. Stool DNA Testing; 4.2.2. By Diagnostic Tool; 4.2.2.1. Biopsy; 4.2.2.2. Blood Tests; 4.2.2.3. Imaging Techniques; 4.2.3. By End User; 4.2.3.1. Hospitals and Clinics; 4.2.3.2. Diagnostic Centers; 4.2.3.3. Research Institutes; 4.2.4. By Region; 4.2.4.1. North America; 4.2.4.2. Europe; 4.2.4.3. Asia Pacific (APAC); 4.2.4.4. Latin America (LATAM); 4.2.4.5. Middle East and Africa (MEA)
5. North America Colorectal Cancer Screening and Diagnostic Market: 5.1. Market Size & Forecast, 2019–2030; 5.1.1. By Value (USD Billion); 5.2. Market Share & Forecast; 5.2.1. By Screening Method; 5.2.2. By Diagnostic Tool; 5.2.3. By End User; 5.2.4. By Country; 5.2.4.1. United States; 5.2.4.1.1. By Screening Method; 5.2.4.1.2. By Diagnostic Tool; 5.2.4.1.3. By End User; 5.2.4.2. Canada; 5.2.4.2.1. By Screening Method; 5.2.4.2.2. By Diagnostic Tool; 5.2.4.2.3. By End User
6. Europe Colorectal Cancer Screening and Diagnostic Market: 6.1. Market Size & Forecast, 2019–2030; 6.1.1. By Value (USD Billion); 6.2. Market Share & Forecast; 6.2.1. By Screening Method; 6.2.2. By Diagnostic Tool; 6.2.3. By End User; 6.2.4. By Country; 6.2.4.1. Germany; 6.2.4.1.1. By Screening Method; 6.2.4.1.2. By Diagnostic Tool; 6.2.4.1.3. By End User; 6.2.4.2. United Kingdom; 6.2.4.2.1. By Screening Method; 6.2.4.2.2. By Diagnostic Tool; 6.2.4.2.3. By End User; 6.2.4.3. Italy; 6.2.4.3.1. By Screening Method; 6.2.4.3.2. By Diagnostic Tool; 6.2.4.3.3. By End User; 6.2.4.4. France; 6.2.4.4.1. By Screening Method; 6.2.4.4.2. By Diagnostic Tool; 6.2.4.4.3. By End User; 6.2.4.5. Spain; 6.2.4.5.1. By Screening Method; 6.2.4.5.2. By Diagnostic Tool; 6.2.4.5.3. By End User; 6.2.4.6. Belgium; 6.2.4.6.1. By Screening Method; 6.2.4.6.2. By Diagnostic Tool; 6.2.4.6.3. By End User; 6.2.4.7. Russia; 6.2.4.7.1. By Screening Method; 6.2.4.7.2. By Diagnostic Tool; 6.2.4.7.3. By End User; 6.2.4.8. The Netherlands; 6.2.4.8.1. By Screening Method; 6.2.4.8.2. By Diagnostic Tool; 6.2.4.8.3. By End User; 6.2.4.9. Rest of Europe; 6.2.4.9.1. By Screening Method; 6.2.4.9.2. By Diagnostic Tool; 6.2.4.9.3. By End User
7. Asia Pacific Colorectal Cancer Screening and Diagnostic Market: 7.1. Market Size & Forecast, 2019–2030; 7.1.1. By Value (USD Billion); 7.2. Market Share & Forecast; 7.2.1. By Screening Method; 7.2.2. By Diagnostic Tool; 7.2.3. By End User; 7.2.4. By Country; 7.2.4.1. China; 7.2.4.1.1. By Screening Method; 7.2.4.1.2. By Diagnostic Tool; 7.2.4.1.3. By End User; 7.2.4.2. India; 7.2.4.2.1. By Screening Method; 7.2.4.2.2. By Diagnostic Tool; 7.2.4.2.3. By End User; 7.2.4.3. Japan; 7.2.4.3.1. By Screening Method; 7.2.4.3.2. By Diagnostic Tool; 7.2.4.3.3. By End User; 7.2.4.4. South Korea; 7.2.4.4.1. By Screening Method; 7.2.4.4.2. By Diagnostic Tool; 7.2.4.4.3. By End User; 7.2.4.5. Australia & New Zealand; 7.2.4.5.1. By Screening Method; 7.2.4.5.2. By Diagnostic Tool; 7.2.4.5.3. By End User; 7.2.4.6. Indonesia; 7.2.4.6.1. By Screening Method; 7.2.4.6.2. By Diagnostic Tool; 7.2.4.6.3. By End User; 7.2.4.7. Malaysia; 7.2.4.7.1. By Screening Method; 7.2.4.7.2. By Diagnostic Tool; 7.2.4.7.3. By End User; 7.2.4.8. Singapore; 7.2.4.8.1. By Screening Method; 7.2.4.8.2. By Diagnostic Tool; 7.2.4.8.3. By End User; 7.2.4.9. Vietnam; 7.2.4.9.1. By Screening Method; 7.2.4.9.2. By Diagnostic Tool; 7.2.4.9.3. By End User; 7.2.4.10. Rest of APAC; 7.2.4.10.1. By Screening Method; 7.2.4.10.2. By Diagnostic Tool; 7.2.4.10.3. By End User
8. Latin America Colorectal Cancer Screening and Diagnostic Market: 8.1. Market Size & Forecast, 2019–2030; 8.1.1. By Value (USD Billion); 8.2. Market Share & Forecast; 8.2.1. By Screening Method; 8.2.2. By Diagnostic Tool; 8.2.3. By End User; 8.2.4. By Country; 8.2.4.1. Brazil; 8.2.4.1.1. By Screening Method; 8.2.4.1.2. By Diagnostic Tool; 8.2.4.1.3. By End User; 8.2.4.2. Mexico; 8.2.4.2.1. By Screening Method; 8.2.4.2.2. By Diagnostic Tool; 8.2.4.2.3. By End User; 8.2.4.3. Argentina; 8.2.4.3.1. By Screening Method; 8.2.4.3.2. By Diagnostic Tool; 8.2.4.3.3. By End User; 8.2.4.4. Peru; 8.2.4.4.1. By Screening Method; 8.2.4.4.2. By Diagnostic Tool; 8.2.4.4.3. By End User; 8.2.4.5. Rest of LATAM; 8.2.4.5.1. By Screening Method; 8.2.4.5.2. By Diagnostic Tool; 8.2.4.5.3. By End User
9. Middle East & Africa Colorectal Cancer Screening and Diagnostic Market: 9.1. Market Size & Forecast, 2019–2030; 9.1.1. By Value (USD Billion); 9.2. Market Share & Forecast; 9.2.1. By Screening Method; 9.2.2. By Diagnostic Tool; 9.2.3. By End User; 9.2.4. By Country; 9.2.4.1. Saudi Arabia; 9.2.4.1.1. By Screening Method; 9.2.4.1.2. By Diagnostic Tool; 9.2.4.1.3. By End User; 9.2.4.2. UAE; 9.2.4.2.1. By Screening Method; 9.2.4.2.2. By Diagnostic Tool; 9.2.4.2.3. By End User; 9.2.4.3. Qatar; 9.2.4.3.1. By Screening Method; 9.2.4.3.2. By Diagnostic Tool; 9.2.4.3.3. By End User; 9.2.4.4. Kuwait; 9.2.4.4.1. By Screening Method; 9.2.4.4.2. By Diagnostic Tool; 9.2.4.4.3. By End User; 9.2.4.5. South Africa; 9.2.4.5.1. By Screening Method; 9.2.4.5.2. By Diagnostic Tool; 9.2.4.5.3. By End User; 9.2.4.6. Nigeria; 9.2.4.6.1. By Screening Method; 9.2.4.6.2. By Diagnostic Tool; 9.2.4.6.3. By End User; 9.2.4.7. Algeria; 9.2.4.7.1. By Screening Method; 9.2.4.7.2. By Diagnostic Tool; 9.2.4.7.3. By End User; 9.2.4.8. Rest of MEA; 9.2.4.8.1. By Screening Method; 9.2.4.8.2. By Diagnostic Tool; 9.2.4.8.3. By End User
10. Competitive Landscape: 10.1. List of Key Players and Their Offerings; 10.2. Global Colorectal Cancer Screening and Diagnostic Market Share Analysis, 2023; 10.3. Competitive Benchmarking, By Operating Parameters; 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
11. Impact of Escalating Geopolitical Tensions on Global Colorectal Cancer Screening and Diagnostic Market
12. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis): 12.1. Epigenomics Inc.; 12.2. Exact Sciences Corporation; 12.3. Eiken Chemical Co. Ltd; 12.4. Polymedco Inc; 12.5. F. Hoffmann-La Roche AG; 12.6. Siemens Healthineers AG; 12.7. Sysmex Corporation; 12.8. Olympus Corporation; 12.9. Biocept Inc.; 12.10. Pathway Genomics Corporation; 12.11. Other Prominent Players
13. Key Strategic Recommendations
14. Research Methodology: 14.1. Qualitative Research; 14.1.1. Primary & Secondary Research; 14.2. Quantitative Research; 14.3. Market Breakdown & Data Triangulation; 14.3.1. Secondary Research; 14.3.2. Primary Research; 14.4. Breakdown of Primary Research Respondents, By Region; 14.5. Assumptions & Limitations

North America Colorectal Cancer Screening Market Size, Share & Industry Trends Analysis Report By Type (Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), By End-user, By Country and Growth Fore

August, 2023 | Published by: Knowledge Based Value (KBV) Research | USD $1,500
Global Colorectal Cancer Screening Market Size, Share & Industry Trends Analysis Report By Type (Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), By End-user, By Regional Outlook and Forecast,

August, 2023 | Published by: Knowledge Based Value (KBV) Research | USD $3,600
Europe Colorectal Cancer Screening Market Size, Share & Industry Trends Analysis Report By Type (Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), By End-user, By Country and Growth Forecast, 2

August, 2023 | Published by: Knowledge Based Value (KBV) Research | USD $1,500
Colorectal Cancer Screening Market, By Screening Tests (Stool-based Tests, Colonoscopy, CT Colonography , Flexible Sigmoidoscopy, Others), By End User (Hospitals, Specialty Clinics, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

May, 2024 | Published by: Coherent Market Insights | USD $4,500
North America Colorectal Cancer Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Modality [Imaging Tests (Colonoscopy, CT Colonography, Flexible Sigmoidoscopy, Capsule Endoscopy, and Others) and Stool-Based Tests (Faecal Immunochemical Test (FIT), Guaiac-Based Faecal Occult Blood Test, and Stool DNA Test)] and End User (Hospitals, Diagnostic Laboratories, Cancer Research Institutes, and Others)

August, 2023 | Published by: The Insight Partners | USD $3,000
Europe Colorectal Cancer Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Modality [Imaging Tests (Colonoscopy, CT Colonography, Flexible Sigmoidoscopy, Capsule Endoscopy, and Others) and Stool-Based Tests (Faecal Immunochemical Test (FIT), Guaiac-Based Faecal Occult Blood Test, and Stool DNA Test)] and End User (Hospitals, Diagnostic Laboratories, Cancer Research Institutes, and Others)

August, 2023 | Published by: The Insight Partners | USD $3,000

PDF E-mail From Publisher:	$4,850
Multi User License (5-7 Users) Fulfilled by Publisher:	$5,750
Global Site License Fulfilled by Publisher:	$8,150

Colorectal Cancer Screening and Diagnostic Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2030, Segmented By Screening Method (Fecal Occult Blood Tests (FOBT), Colonoscopy, Sigmoidoscopy, CT Colonography (Virtual Colono

Research Assistance

Other tasks

Colorectal Cancer Screening and Diagnostic Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2030, Segmented By Screening Method (Fecal Occult Blood Tests (FOBT), Colonoscopy, Sigmoidoscopy, CT Colonography (Virtual Colono

North America Colorectal Cancer Screening Market Size, Share & Industry Trends Analysis Report By Type (Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), By End-user, By Country and Growth Fore

Global Colorectal Cancer Screening Market Size, Share & Industry Trends Analysis Report By Type (Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), By End-user, By Regional Outlook and Forecast,

Europe Colorectal Cancer Screening Market Size, Share & Industry Trends Analysis Report By Type (Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), By End-user, By Country and Growth Forecast, 2

Colorectal Cancer Screening Market, By Screening Tests (Stool-based Tests, Colonoscopy, CT Colonography , Flexible Sigmoidoscopy, Others), By End User (Hospitals, Specialty Clinics, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Research Assistance

Other tasks